Muhammad Ali, Kendrick Koo, David Chang, Phil Chan, Sheng F Oon, Daniel Moon, Declan G Murphy, Renu Eapen, Jeremy Goad, Nathan Lawrentschuk, Arun A Azad, Sarat Chander, Mark Shaw, Nicholas Hardcastle, Shankar Siva
BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is an emerging treatment for patients with primary renal cell carcinoma (RCC). However, its impact on renal function is unclear. This study aimed to evaluate incidence and clinical factors predictive of severe to end-stage chronic kidney disease (CKD) after SABR for RCC. METHODS AND MATERIALS: This was a Single institutional retrospective analysis of patients with diagnosed primary RCC receiving SABR between 2012-2020...
February 15, 2024: Radiation Oncology